The companies reached an agreement to settle in the amount of Dollars 775 Million.
Johnson & Johnson receives subpoenas from the Security and Exchange Commission and Justice Department related to lawsuits over its baby powder line; new study based on Bureau of Labor statistics data shows the highest-paying jobs for women in the U.S. Plaintiffs in Xarelto lawsuits claimed the drug's manufacturers had a responsibility to warn patients of its dangers and lack of antidote rather than focusing exclusively on its potential selling points. The settlement will close the litigation, thus saving the company huge costs of keeping the litigation open any further. In 2018, it generated $4.07 billion in revenue for the company.
"Bayer continues to believe these claims are without merit and there is no admission of liability under the agreement", it said.
Bayer and Janssen each pay half of the settlement amount.
The case is In re: Xarelto (rivaroxaban) Products Liability Litigation, case number 2:14-md-02592 in the U.S. District Court for the Eastern District of Louisiana.
Xarelto (rivaroxabin) received FDA approval in 2011 as a way of preventing deep vein thrombosis, possibly leading to pulmonary embolism, in patients undergoing joint replacement surgery.
It is prescribed for people with atrial fibrillation, a common heart rhythm disorder that increases the risk of stroke.
The majority of the claims were consolidated in New Orleans federal court, where three cases were selected as so-called bellwether trials, aimed to help determine the range of damages and define settlement options.
Over five years after the litigation began, Bayer and Janssen Pharmaceuticals prevailed in all six cases that went to trial.
Most of the lawsuits over Eliquis have been dismissed by United States judges.
A similar drug, Boehringer Ingelheim's Pradaxa, also became subject of thousands of lawsuits claiming the company understated its bleeding risk.